CAS 1380723-44-3: Atezolizumab

Description: Atezolizumab is a monoclonal antibody that functions as an immune checkpoint inhibitor, specifically targeting the programmed death-ligand 1 (PD-L1). It is primarily used in the treatment of various cancers, including non-small cell lung cancer and urothelial carcinoma. The mechanism of action involves blocking the interaction between PD-L1 and its receptors, PD-1 and B7.1, thereby enhancing T-cell activation and promoting an immune response against tumor cells. Atezolizumab is administered via intravenous infusion and is characterized by its humanized IgG1 structure, which contributes to its stability and efficacy. The drug is typically associated with a range of potential side effects, including immune-related adverse events, due to its mechanism of enhancing immune activity. Its development represents a significant advancement in cancer immunotherapy, providing a therapeutic option for patients with advanced malignancies. As with all monoclonal antibodies, careful monitoring during treatment is essential to manage any adverse reactions effectively.

Formula: Unspecified

Synonyms:

• Immunoglobulin G1, anti-(human programmed death-1 ligand-1) (human monoclonal MPDL3280A heavy chain), disulfide with human monoclonal MPDL3280A κ-chain, dimer
• Atezolizumab
• Immunoglobulin G1, anti-(human CD antigen CD274) (human monoclonal MPDL3280A heavy chain), disulfide with human monoclonal MPDL3280A κ-chain, dimer
• MPDL 3280A
• RG 7446

Atezolizumab

CAS: 1380723-44-3

• Formula: C₃₇H₆₂N₄O₂S
• Purity: 99%
• Molecular weight: 626.9788

Atezolizumab

CAS: 1380723-44-3

Atezolizumab is an antibody inhibitor, a humanized monoclonal antibody, IgG1, which targets PD-L1. Atezolizumab has …

• Purity: 95.10% - 99.3% （SEC-HPLC）
• Color and Shape: Liquid
• Molecular weight: 145 kDa

Atezolizumab

CAS: 1380723-44-3

Monoclonal antibody against PDL-1; anti-cancer agent

• Purity: Min. 95%
• Color and Shape: Clear Liquid